beta-peptide immunization: a possible new treatment for Alzheimer disease.

Research on the pathophysiological characteristics of Alzheimer disease (AD) over the past decade has been directed toward the ultimate goal of developing a disease-modifying treatment to control or prevent the disease. A report recently published in Nature 1 describes for the first time a treatment that may both prevent and treat the progression of Alzheimer disease. The treatment ironically involves immunization with the pathological β-amyloid peptide itself to generate an immune response targeted against the amyloid plaques in the brain. These findings have raised a number of scientific and clinical questions that are discussed below.

[1]  I. Lieberburg,et al.  Cellular mechanisms of beta-amyloid production and secretion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[3]  L. Thal,et al.  Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.

[4]  C. Lippa,et al.  Aβ−42 deposition precedes other changes in PS-1 Alzheimer's disease , 1998, The Lancet.

[5]  D. Price,et al.  Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. , 1997, Human molecular genetics.

[6]  J. Trojanowski,et al.  Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[7]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[8]  R. Broadwell,et al.  Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium III. Receptor-Mediated Transcytosis through the Blood–Brain Barrier of Blood-Borne Transferrin and Antibody against the Transferrin Receptor , 1996, Experimental Neurology.

[9]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[10]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[11]  L. Mucke,et al.  Neurotrophic and Neuroprotective Effects of hAPP in Transgenic Mice a , 1996, Annals of the New York Academy of Sciences.

[12]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[13]  J. Higaki,et al.  Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism , 1995, Neuron.

[14]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[15]  U. Wurster,et al.  Passage of intravenous immunoglobulin and interaction with the CNS. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[16]  D. Selkoe,et al.  Alzheimer's Disease: A Central Role for Amyloid , 1994, Journal of neuropathology and experimental neurology.

[17]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[18]  M. Sofroniew,et al.  Serum Proteins Bypass the Blood-Brain Fluid Barriers for Extracellular Entry to the Central Nervous System , 1993, Experimental Neurology.

[19]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[20]  E. Thompson,et al.  Laboratory Investigation of Cerebrospinal Fluid Proteins , 1990, Annals of clinical biochemistry.

[21]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[22]  D. Selkoe,et al.  A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity , 1998 .

[23]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.